VTRS
$13.74+0.23 (+1.74%)
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: ...
Recent News
What Are Analysts Saying About Viatris Inc (VTRS) Stock?
Viatris Inc. (NASDAQ:VTRS) is one of the 13 extreme value stocks to buy now. Viatris Inc. (NASDAQ:VTRS) is covered by 12 analysts on Wall Street with a medium price target of $16, suggesting 12.36% upside from current levels. On February 27, Truist Financial analyst Les Sulewski raised the firm’s price target on the stock from […]
Assessing Viatris (VTRS) Valuation After Mixed Short And Long Term Share Price Moves
Why Viatris (VTRS) Is On Investors’ Radar Viatris (VTRS) is drawing attention after a mixed stretch in its share performance, with a negative move over the past month but a positive total return over the past 3 months and year. See our latest analysis for Viatris. At a share price of US$13.51, Viatris has recently seen a 16.24% 1 month share price decline after a strong 15.97% 3 month share price return, set against a 55.38% 1 year total shareholder return that hints at shifting sentiment...
UBS and BofA Lift Price Targets on Viatris (VTRS)
Viatris Inc. (NASDAQ:VTRS) is one of the 10 Best Stocks Under $20 to Buy According to Hedge Funds. On February 27, UBS raised its price target on Viatris Inc. (NASDAQ:VTRS) from $18 to $20 and maintained a Buy rating. UBS said the company achieved expected cost-saving targets and the company’s fiscal year 2026 guidance came […]
Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug
Celcuity develops targeted cancer therapies and diagnostics, leveraging proprietary technology to advance precision oncology solutions.
Sector Update: Health Care Stocks Retreat Late Afternoon
Health care stocks declined late Thursday afternoon, with the NYSE Health Care Index down 1.3% and t